Drugs / GXV813
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07467993 | Mar 2026 → Jul 2027 expected | schizophrenia | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GXV813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07467993 ↗ |
| Route | Oral | “GXV813 administered orally.” NCT07467993 ↗ |